ReviewInternational journal of nanomedicine2026
From Nature to Nanomedicine: Engineered Plant-Derived Nanovesicles for Skin Disease.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-derived nanovesicles (PDN), as a novel class of natural nanocarriers, possess excellent biocompatibility and the capacity to load various bioactive components, offering new perspectives for the treatment of skin diseases. However, natural PDN suffer from limited skin penetration and weak targeting ability. By applying engineering strategies such as chemical modification and membrane hybridization, these intrinsic limitations can be effectively overcome, thereby markedly enhancing their therapeutic efficacy against skin diseases. This review provides a systematic summary of the fundamental characteristics and engineering strategies of PDN. Based on the latest research advances, we also outline their therapeutic applications across various skin diseases, including inflammatory, infectious, wounds, aging-related, pigmentary, and tumors. In addition, we propose lesion-adapted administration strategies tailored to different skin diseases. We further highlight the major translational challenges and future opportunities of PDN, providing insight into how these engineered natural nanocarriers may reshape precision and next-generation therapies for skin diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.